Hana Securities has forecasted that Celltrion will continue to grow by expanding its presence in the U.S. biosimilar market. The firm initiated coverage with a 'buy' recommendation and set a target price of 310,000 won.
On the 18th, Kim Seon-ah, a researcher at Hana Securities, stated in a report, "The five newly launched products are driving revenue growth, and as the sales proportion of these new products increases, the operating profit margin is also improving."
Celltrion's consolidated revenue for the third quarter of this year reached 1.58 trillion won, a 53% increase compared to the same period last year. Operating profit rose to 525.3 billion won, up 74%. Kim noted, "While there is currently no profit contribution due to amortization costs from acquisitions, the contract manufacturing organization (CMO) revenue from Eli Lilly, which began this year, is also contributing to the increased revenue."
Hana Securities estimates Celltrion's annual revenue for this year will be 5.85 trillion won, with operating profit projected at 1.9 trillion won. This exceeds the company's guidance of 5.3 trillion won in revenue and 1.8 trillion won in operating profit. Kim emphasized, "A key point to note in the company's performance growth is that direct sales results in the U.S. are being observed in earnest starting this year, driven by the newly launched products. We can expect continued growth as more commercialized products are added in the future."
He added, "To expand welfare within a limited budget, the use of biosimilars must be encouraged, and companies with high biosimilar sales in the U.S. will inevitably attract market attention." He also stressed the need to maintain interest in Celltrion, which is solidifying its position and increasing its market share in the U.S. next year.
The potential for a reassessment of corporate value due to the expansion of U.S. operations was also highlighted. Kim predicted, "The increase in revenue by 2027 will likely depend on the sales of new products in the U.S., and if Celltrion can confirm high demand for its biosimilars in the U.S. through quarterly results, the stock price could rapidly rise beyond previous peaks."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.